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Dementia  with  Lewy  bodies  (DLB)  is  a serious  age-dependent  human  neurodegenerative  disease,  with
multiple  debilitating  symptoms,  including  dementia,  psychosis  and  signiﬁcant  motor  deﬁcits,  but with
little or no effective  treatments.  This  comparative  ligand  autoradiographical  study  has  quantiﬁed  his-
tamine  H3 receptors  (H3R)  in  a  series  of major  cortical  and  basal  ganglia  structures  in human  DLB  and
Alzheimer’s  (AD)  post-mortem  cases  using  the  highly  selective  radioligand,  [3H] GSK189254.
In the  main,  the  levels  of H3 receptor  were  largely  preserved  in DLB cases  when  compared  with  aged-
matched  controls.  However,  we  provide  new  evidence  showing  variable  levels  in  the  globus  pallidus,LB
sychosis
lobus pallidus
istamine
3R
and,  moreover,  raised  levels  of  Pallidum  H3 correlated  with  positive  psychotic  symptoms,  in particu-
lar  delusions  and  visual  hallucinations,  but  not  symptoms  associated  with depression.  Furthermore,  no
correlation  was  detected  for  H3 receptor  levels  to MMSE  or  IUPRS  symptom  severity.
This  study  suggests  that H3R  antagonists  have scope  for  treating  the  psychotic  symptomologies  in DLB
and  other  human  brain  disorders.
© 2016  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).. Introduction
Dementia with Lewy bodies (DLB) is the second most preva-
ent human dementia. This is a seriously debilitating human
isease, with multiple prevalent symptoms, including dementia,
sychosis (hallucinations and ﬂuctuating consciousness) and sig-
iﬁcant motor deﬁcits, but with little or no effective treatments
1]. The histaminergic system plays an important role in central
ervous system regulation and behaviour through its role as an
utoreceptor, regulating the synthesis and release of histamine and
s a heteroreceptor, negatively regulating the release of a variety
f other key neurotransmitters including acetylcholine, dopamine,
lutamate and gamma-aminobutyric acid [2–4]; reviewed in [5].
iven its widespread distribution and inﬂuence upon multiple
eurotransmitter systems, H3 antagonists are promising clinical
Abbreviations: DLB, Dementia with Lewy Bodies; AD, Alzheimer’s Disease;
DHD, attention deﬁcit hyperactivity disorder; NFTs, neuroﬁbrillary tangles; PM,
ost mortem delay; RMHA, R--methylhistamine; MMSE, Mini Mental State
xamination; UPDRS, Uniﬁed Parkinson Disease Rating Scale; MCID, Microcomputer
maging Device.
∗ Corresponding author at: Department of Biosciences, University of Durham,
outh Road, Durham, DH13LE, UK.
E-mail address: paul.chazot@durham.ac.uk (P.L. Chazot).
ttp://dx.doi.org/10.1016/j.phrs.2016.08.034
043-6618/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article ucandidates for the treatment of age-related dementias, such as DLB
[6–8].
There are indications that histamine deﬁcits are present in
dementias, such as Alzheimer’s Disease (AD), however it is
unknown whether these are speciﬁc to certain brain regions,
changes in histamine receptor numbers, or are speciﬁc for AD
amongst other neurodegenerative disorders. The importance of the
histaminergic system in AD is difﬁcult to assess due to a number of
conﬂicting reports. For example, histamine levels in AD brains have
been reported to be increased in temporal and frontal cortex, basal
ganglia and hippocampus [9]. However, other studies have shown
decreases in histamine content in the hypothalamus, hippocam-
pus and temporal cortex [10,11]. Histaminergic cell bodies are also
located in the TMN, where neuroﬁbrillary tangles (NFTs) are also
found. NFTs are particularly concentrated in the region containing
histaminergic perikarya compared with surrounding areas [12,13]
and together with cholinergic basal forebrain nuclei, the TMN has
been described as an early affected subcortical nucleus for the pres-
ence of NFT [14]. The number of histaminergic cell bodies in the
TMN  was shown to be similar to that of normal brains [12]. In con-
trast, another group showed a signiﬁcant reduction in large-sized
histamine containing neurons in the TMN  where numerous NFTs
were found, indicative of a central histaminergic dysfunction [13].
Histamine decarboxylase (HDC) activity, also a common marker of
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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he histaminergic system, has been shown to be decreased in AD
ompared with elderly controls [15]. Whilst there are conﬂicting
ata about the histamine content in the brain of AD patients, one
ecent study using a highly selective H3R ligand had shown the level
f H3R expression to be unaltered in the late stages of human AD
ompared to age matched controls, as well as in TASTPM mice (a
ouse model of AD) compared with wild type mice [6,16].
Understanding the molecular structure of the H3R has increased
onsiderably and a number of H3R antagonists have been identiﬁed
nd a few (pitolisant and GSK189254) have entered advanced clin-
cal development focusing on narcolepsy, cognitive and psychotic
isorders [8,18,19]. The histaminergic system innervates several
tructures that are known to be involved in cognition such as the
asal forebrain, cerebral cortex, cingulate cortex, amygdala and
halamus [20]. High levels of H3R have been shown to be expressed
n the cerebral cortex [21], which is densely innervated by cholin-
rgic neurons. In neuropsychiatric disorders such as AD, attention
eﬁcit hyperactivity disorder (ADHD) and schizophrenia, cogni-
ive deﬁcits play a major role in the disease [22]. Increased brain
istamine is also positively correlated with age and may  play a
ole in decreasing acetylcholine uptake [23]. It is thought that H3R
ntagonists may  be able to prevent the reduction in acetylcholine
hrough its heteroreceptor characteristic [24–26]. H3Rs are also
ighly expressed in the basal ganglia in both rodent and human
rains [27–29].
Ligand autoradiography is a very useful technique to deﬁne
he topology and quantify receptors in post-mortem brain slices.
SK189254 is derived from a novel benzazepine series of H3R
ntagonists [6] that are structurally distinct from other recently
escribed non-imidazole H3R antagonists. GSK18925 has been
hown to signiﬁcantly improve performance of rats in diverse cog-
ition paradigms, including passive avoidance, water maze, object
ecognition and attentional set shift [4,5]. The data thus far for H3R
ntagonists point to a possible therapeutic potential for diseases
here cognitive deﬁcits are already present such as AD and other
ementias, including DLB. These complex brain diseases also dis-
lay multiple symptoms in addition to dementia which may  be
argeted through the histaminergic system. In this present study,
3H] GSK189254 was utilised to quantify levels of cortical and basal
anglia H3Rs in normal human aged post-mortem brains, and in a
eries of DLB and AD cases (the latter for comparative purposes)
ith detailed connected clinical information.
. Materials & methods
.1. Determining the working concentration of [3H] GSK189254
or autoradiography
Saturation binding assays using [3H] GSK189254 were per-
ormed essentially as described previously [6], in 50 mM Tris-HCl,
H 7.7 containing 5 mM EDTA and a concentration range of
.01–8 nM for radioligand. Non-speciﬁc binding was determined
sing 1 M R--methylhistamine (RMeH). The assay was termi-
ated by rapid ﬁltration through a Whatman GF/B ﬁlters pre-soaked
n 10 mM sodium phosphate dibasic pH 7.4, which were washed
3 × 3 ml)  using iced cold 10 mM sodium phosphate dibasic pH 7.4,
sing a Brandell 24-place cell harvester.
[3H] GSK189254 bound selectively to the hH3R vs hH4R, and the
wo major hH3R isoforms, namely hH3 445 and hH3 365, transiently
xpressed in HEK293 cells [6], displayed very similar KD values of
.16 ± 0.04 and 0.24 ± 0.07 nM,  respectively (Supplementary Fig. 1).
he concentration of radioligand used was, therefore, selected as
pproximately 2× mean KD to ensure that each autoradiography
un detected at least 65% of available receptor binding sites.ical Research 113 (2016) 245–256
2.2. Human case details and diagnostic criteria
All human brain tissue were obtained from Newcastle Brain Tis-
sue Resource Bank LREC (Newcastle and Tyneside) with full ethical
approval (2002/295). Frozen tissue was  collected at autopsy and
1 cm coronal slices from the left hemisphere were snap frozen in liq-
uid Arcton (ICI) and stored at −70 ◦C. The sections were then stored
at −80 ◦C. Prior to sectioning, tissue slices were warmed to 15 ◦C and
blocks containing the striatum were sub-dissected and mounted
onto cryostat chucks with 8% carboxymethylcellulose. Coronal sec-
tions were cryostat sectioned at a thickness of 20 m using a Brights
OTF cryostat onto Vectabond-coated glass slides, air dried for 1–2 h
and stored at −80 ◦C prior to receptor autoradiography. The right
hemisphere was  used for histopathological examination, following
formalin ﬁxation and parafﬁn embedding. Cortical and hippocam-
pal neuroﬁbrillary tangles were demonstrated using a modiﬁcation
of Palmgren’s silver technique [30] and the von Braunmühl silver
impregnation technique [31] was used to identify senile plaques
in 25 m thick frozen sections cut from tissue blocks adjacent to
those taken for parafﬁn processing. Counts of NFTs and neuritic
plaque number were made from ﬁelds across the entire cortical rib-
bon, as described in [32]. Lewy-bodies in the substantia nigra were
visualised by the use of haematoxylin and eosin staining, cortical
Lewy-bodies and dystrophic neuritis were detected using ubiquitin
immunohistochemistry on 5 m thick parafﬁn embedded sections.
Neurones in the substantia nigra were quantiﬁed following cresyl
fast violet staining of 20 m thick parafﬁn sections.
Control cases had no history of psychiatric or neurological disor-
der and had no neuropathological indications of Lewy-body disease
(DLB) or any other neurological disorder. DLB cases were clinically
diagnosed by the presence of a progressive cognitive impairment
seen in conjunction with at least two  of the following symptoms:
recurrent visual hallucinations; ﬂuctuating cognition with pro-
nounced variations in attention and alertness; spontaneous motor
features of parkinsonism [33]. DLB cases were distinguished from
AD by the presence of brain stem and cortical Lewy-bodies, Lewy
neurites in the CA2/3 and endplate segments of the hippocampus
[33], and by lower or moderate Alzheimer-type pathology with
fewer NFT than found in AD.
2.3. Human cases used
The 43 cases selected for this study were cut at the level of the
striatum (caudate nucleus and putamen) corresponding to coronal
brain levels 9–15 using the Coronal Map  of Brodmann Areas in the
human Brain [34]. Of the 43 cases, 12 were control cases, 16 DLB
cases and 15 AD cases (Table 1). For each case 5 replicates were
used to measure 3 total and 2 non-speciﬁc radioligand binding.
Summary of the 43 human cases chosen for the study. PM
delay = post mortem delay, that is, time between death and freezing
of the tissue to allow for post-mortem examination.
No signiﬁcant differences were seen with age or PM delay in
these cases (p > 0.05). No gross signiﬁcant differences were seen
between the male and female cases in respective groups (p > 0.05)
(not shown).
2.4. In vitro autoradiography of human brain tissue using [3H]
GSK189254
The autoradiography method used was essentially as described
previously [6]. In brief, human brain sections were left to equili-
brate to room temperature for 1 h before the protocol commenced.
Human sections were incubated in (50 mM Tris, 5 mM EDTA pH 7.7)
containing 2 × KD (approximately 0.5 nM)  [3H] GSK189254 (spe-
ciﬁc activity = 81Ci/mmol, stored at −20 ◦C, gift from Dr Medhurst,
GSK, Harlow, UK) for 1 h at RT, until equilibrium is reached. Non-
N.L. Lethbridge, P.L. Chazot / Pharmacological Research 113 (2016) 245–256 247
Table  1
Summary of 43 human cases.
n = Age (years) PM Delay (hours)
Total Females Males Range Mean SD Range Mean SD
Control 12 7 5 70–91 80.92 6.97 10–96 42 22.44
DLB  16 8 8 64–87 77.13 7.19 4–60 31.56 18.18
AD  15 9 6 74–91 83.27 4.53 4–82 33.40 21.69
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peciﬁc binding was deﬁned using 10 M unlabelled RMHA. The
eaction was terminated by ﬁve 3 min  washes in 50 mM Tris, 5 mM
gCl pH 7.7, at 4 ◦C and a ﬁnal wash in dH2O at 4 ◦C. Sections were
eft to dry in a stream of cold air for 1–2 h. The sections were then
ransferred to X-ray cassettes, each including tritium autoradio-
raphical microscale as calibration standards, and exposed against
ritium-sensitive hyperﬁlm for 6 weeks at 4 ◦C. The exposed ﬁlms
ere then developed in D-19 developer (Kodak, UK) for 5 min  at RT,
xed for 6 min  in Uniﬁx (Kodak, UK), washed under running water
or 20 min  and air-dried.
.5. Image analysis
The resulting brain images on the ﬁlm were captured using a
age 72 MTI  CCD72S video camera and were quantitatively ana-
ysed by computer-assisted densitometry using Microcomputer
maging Device (MCID Elite) version 7.0 software from imaging
esearch Inc., Ontario, Canada. The radioactive Tritium standards
ere used to calculate a standard curve for each autoradiogram,
hich allowed the conversion from optical density values to units
f concentrations for each brain region analysed. Non-speciﬁc bind-
ng tissue sections were present on the same ﬁlm as each of the
orresponding total binding tissue sections for the same case. Spe-
iﬁc binding was determined by subtracting mean non-speciﬁc
inding from mean total binding. Brain structures were identiﬁed
y reference to the atlas of the Human Brain [34] and the mean and
tandard deviations for each brain structure in each section were
alculated. Inter-assay variability was reduced by using ligand con-
entrations that were at least twice the ligand afﬁnity, using ligand
rom the same batch for each autoradiographical run, and by stan-
ardising each ﬁlm using calibration microscales. All sections were
hen re-analysed and results conﬁrmed by digital autoradiogra-
hy using a Beta-Imager 2000 instrument (Biospace, Paris, France),
adioactivity was measured by counting the number of  particles
rom delineated areas and the results are expressed as mean spe-
iﬁc binding counts per minute per square millimetre (cpm/mm2;
 = 12–16 cases per group).
.6. Symptom analysis
.6.1. The mini mental state examination (MMSE)
The MMSE, validated and widely used since its creation in
975, is an effective tool for assessing cognitive mental status. The
MSE is used to detect cognitive impairment and monitor response
o treatment. It is an eleven question test covering ﬁve areas of
ognitive function: orientation, attention/calculation, recall and
anguage, and the ability to follow simple verbal and written com-
ands [35]. A score of 23 or below, from a possible 30 is indicative
f cognitive impairment. The test is effective but does have limita-
ions, for example, patients who are hearing and visually impaired
r who have low English literacy, or with communication disor-
ers may  perform poorly even when cognitively intact [35]. The
est provides a total score that places the individual on a scale of
ognitive function. The values used in this were those taken at the
ast assessment before death of the patient.that is, time between death and freezing of the tissue to allow for post-mortem
2.6.2. Uniﬁed Parkinson disease rating scale (UPDRS)
The UPDRS is a rating tool to follow the longitudinal course of PD.
It is made up of the 1) Mentation, Behaviour and Mood, 2) Activities
of Daily Living (ADL) and 3) Motor sections. These are evaluated by
interview. Some sections require multiple grades assigned to each
extremity. A total of 199 points are possible, where 199 represent
the worst (total) disability, and 0 represents no disability [36]. The
values used in this study were those taken at the last assessment
before death of the patient.
Estimated lines of best ﬁt for MMSE  and UPDRS correlations
were produced using GraphPad Prism and are represented on each
graph, indicating any changes in binding levels in each tissue with
increasing clinical score. The signiﬁcance of the regression was
determined from the generated p value, where p ≤ 0.05 was con-
sidered to show a signiﬁcant linear relationship between clinical
score and binding level.
2.6.3. Other symptom analysis
Data relating to depression, delusions, dementia and visual hal-
lucinations experienced by each subject in life were also studied.
The severity of the symptoms experienced were measured on the
following scale, 0 = none, 1 = mild, 2 = severe, and are indicative of
the last assessment before death of the subject. In each case and
in each tissue investigated, attempts were made to correlate the
speciﬁc binding levels of [3H] GSK189254 data with a range of
relevant clinical data scores. The depression, delusion and visual
hallucination scores were displayed: 0 no symptoms and 1+ show-
ing symptoms, giving the mean score ± SD against binding levels in
cpm/mm2.
2.7. Statistical analysis
Statistical analysis performed involved correlation analysis and
students unpaired t-test, to analyse individual regions of the brain.
Graphs and one-way ANOVA with appropriate post-hoc test were
constructed using GraphPad Prism version 4. Statistical signiﬁcance
was set at p < 0.05.
3. Results
3.1. Human H3R pharmacology of [3H] GSK189254
The selectivity of [3H] GSK189254 for the human H3R 445 in
comparison to the closely related human H4R 390 subtype was
investigated. No signiﬁcant binding was  observed for the hH4
receptor (Supplementary Fig. 1) Moreover, very similar Kd values
(ca. 0.3 nM)  for [3H] GSK189254 were observed with two  of the
most common, in cortical-striatal regions, human H3R isoforms,
H3R 445 and H3R 365 expressed alone or in combination in HEK293
cells (Supplementary Fig. 1). A representative digital photographic
examplar of speciﬁc [3H] GSK189254 binding shows the high levels
of speciﬁc binding in the human brain slice. Very low non-speciﬁc
binding (<5%) was  achieved with the methodology utilised in this
study. High binding levels were detected in various cortical (insular,
anterior cingulate) and striatal (caudate, putamen, globus pallidus,
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ucleus accumbens) regions (Supplementary Fig. 1) all relevant to
ymptomology of DLB.
.2. Age-dependence of [3H] GSK189254 binding in control and
ementias
DLB cases were ﬁrst examined for [3H] GSK189254 binding lev-
ls in the various cortical and striatal brain regions spanning an
ge range of 60–80 years. There were no signiﬁcant age-dependent
hanges in all brain regions analysed although individual variation
as clear (p ≥ 0.1 in all areas) (Fig. 1). A similar lack of change was
bserved in both control and AD cases over the age-range explored
not shown).
.3. [3H] GSK189254 binding levels in control and dementia cases
As there were no clear changes in [3H] GSK189254 binding levels
cross the age-range, the data sets were pooled and a compari-
on made between controls and the two dementias. No signiﬁcant
ifferences were observed in the mean binding densities of [3H]
SK189254 binding in all brain regions analysed (Fig. 2). The data
ere further analysed for gender differences (not shown), simi-
ar levels of binding was seen in both female and male cohorts in
ll brain regions, apart from minor changes in the globus pallidus,
ndicating little or no evidence for gender bias.
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3.4. Correlation of [3H] GSK189254 binding levels to cognitive
and motor deﬁcits
The clinical data corresponding to DLB and AD cases summarised
in Table 1 were further analysed to determine if there were any cor-
relation between [3H]GSK189254 binding and MMSE (mini mental
state examination) (Fig. 3) and UPDRS scores (Uniﬁed Parkinson
disease rating scale) (Fig. 4). There was no signiﬁcant correlation in
the binding densities of [3H] GSK189254 with MMSE  score (p ≥ 0.5)
in all areas in DLB cases. There was also no signiﬁcant correlation
in the binding densities of [3H] GSK189254 with MMSE score in AD
cases analysed in parallel (p ≥ 0.2 in all areas) (Supplementary Fig.
2).
Moreover, there were also no signiﬁcant differences in the bind-
ing densities of [3H] GSK189254 with increased UPDRS  score in DLB
(Fig. 4) and AD cases (Supplementary Fig. 3).
3.5. Correlation of [3H] GSK189254 binding levels to affective and
psychotic deﬁcits
In many cases investigated, clinical information relating to
depression and psychosis symptoms were recorded. There were
no signiﬁcant differences between the H3R binding densities in
DLB (Fig. 5) and AD cases (Supplementary Fig. 3). with and without
depression in all brain structures investigated.
Similarly, there were no signiﬁcant differences between the
H3R binding densities in DLB cases with and without severe delu-
sions, except in the globus pallidus where a signiﬁcant increase in
H3R binding was observed in cases with severe delusions (p < 0.01)
(Fig. 6).
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C)  Cingulate cortex, (D) Insular cortex, (E) external Globus Pallidus, (F) internal 
tructures investigated.
There were no signiﬁcant differences between the H3R binding
ensities and severity of visual hallucinations, although there is an
ncreased H3R binding in the globus pallidus associated with severe
isual hallucinations.Overall H3R binding in both AD and DLB cases does not show any
orrelation with MMSE, UPDRS, and depression symptoms in cor-
ical or striatal structures in the human CNS. In contrast, increased
3R binding positively correlated with increased severity of psy-al patient cases) for pooled Control, DLB and AD cases for (A) Caudate, (B) Putamen,
s Pallidus. No signiﬁcant differences in binding levels was observed in the brain
chotic symptoms (delusions and visual hallucinations) in the globus
pallidus in both DLB Figs. 6 and 7 and AD (Supplementary Fig. 4 and
5) cases.4. Discussion and conclusion
The high afﬁnity and selective H3R antagonist/inverse agonist
[3H] GSK189254 provides an ideal tool to visualise and allow quan-
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lobus  pallidus, (F) Internal globus pallidus. No signiﬁcant relationship was see wit
iﬁcation of the human histamine H3R. The ligand displays a high
fﬁnity for two of the most common human H3R isoforms, and
lso very low non-speciﬁc binding properties, which makes it
n ideal ligand autoradiographical tool and a vast improvement
n previously utilised radioligands (e.g. RMethylhistamine and
lobenpropit [37]). A range of brain structures implicated in the
haracteristic symptoms of DLB and AD were investigated. The
triatum has a well-known role in planning and modulation of
ovement pathways, but is also involved in a variety of other cog-
itive processes involving executive function. The cerebral cortex
s involved in many complex brain functions including memory
rocessing, attention, perceptual awareness, language and con-
ciousness. More speciﬁcally, the anterior cingulate cortex and
lobus pallidus are thought to be major neuroanatomical interface
etween emotion and cognition, and the insular cortex is believedin (A) Caudate, (B) Putamen, (C) Cingulate cortex, (D) Insular cortex, (E) External
brain structures investigated (each point is an individual DLB patient case).
to process convergent information to produce an emotionally rele-
vant context for sensory experience. The main focus of this present
study was  to determine any changes in the H3R in relation to
age and gender in control, DLB and AD cases, and relationship to
speciﬁc symptoms displayed by the individuals. Several lines of
evidence suggest that manipulation of the histamine system may
alleviate some of the clinical symptoms of AD and DLB. H3R block-
ade with antagonist/inverse agonists results in the up-regulation of
several neurotransmitters which have been shown to have positive
affects upon cognitive deﬁcits in several animal models of dementia
(reviewed in [8] and [11]).
Previous ligand autoradiography studies using less selective
H3R radioligands have reported high H3R densities in the internal
and external segments of the globus pallidus, caudate, putamen
and nucleus accumbens with moderate levels in the anterior cin-
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ortex,  (E) External globus pallidus, (F) Internal globus pallidus. Each point is an ind
ulate and insular cortices [38,39] which concurs well with the
resent study. Furthermore, in this present study, no signiﬁcant
ifferences were observed with age although this was only over
he restricted 60–80 age range; changes prior to 60 years of age
ay  have occurred and require further investigation. Using [3H]
lobenpropit it was also reported that no signiﬁcant age-related
hanges in H3R expression in the basal ganglia occurred in normal
geing, nor did receptor density differ signiﬁcantly between male
nd female cases [37]. Therefore, H3R levels does not appear to be
rossly altered in the latter stages of normal aging.
H R binding levels were next determined in DLB to establish3
hether disease state alters receptor levels. H3R binding densities
n both cortical and striatal regions in DLB human cases showed no
igniﬁcant differences in ligand binding with age, which supportedSK189254 in DLB cases in (A) Caudate, (B) Putamen, (C) Cingulate cortex, (D) Insular
l DLB patient case.
previously published data suggesting that the H3R is preserved
in two common age-related dementias, namely AD and vascular
dementias, in other cortical and limbic regions [40]. This was  also
conﬁrmed in this present study with different AD cases and dif-
ferent cortical brain structures. Overall, these data suggest that
there is no gross decline in H3R population between control and
disease cases, providing further evidence for H3R preservation
across a range of neurodegenerative diseases. Preclinical trials have
already alluded to the prospect of H3R antagonists as a treatment
for cognitive impairment. We  provide further evidence showing
preservation of H Rs in many cortical and striatal brain regions in3
AD but also in DLB, promoting the H3R as a viable general target in
treating a range of human dementias. This has yet to be realised in
the clinic.
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igniﬁcant correlation was  observed between [3H] GSK189254 binding levels and
ases.
The data set produced was further interrogated with respect to
elective symptoms present in the dementia cohorts prior to death
nd relationship to H3R expression. The H3R binding levels were
orrelated with symptom severity scores from various validated
linical tests. There was no correlation between H3R binding levels
nd MMSE or UPDRS scores in both DLB and AD cases, indicating
hat the H3R expression levels in the brain structures investigated
o not inﬂuence the severity of cognitive and mobility impairment,
espectively. The latter is in contrast with reported higher H3R bind-
ng levels observed in the motor loop structures, substantia nigra
nd ventral striatum in PD animal studies (e.g. [41]). These trans-
ational discrepancies highlight the importance of promoting more
uman postmortem and live imaging brain studies. There was  a
odest overall increase in H3R binding sites with decrease in MMSE
core indicative of cognitive function. The increase in H3R binding
aybe acting as a compensatory mechanism to counteract changes9254 in DLB cases in (G) Nucleus Accumbens, (H) combined Globus Pallidus. No
ssion scores in all brain structures investigated. N = number of individual Disease
seen elsewhere in the histaminergic system in severe AD and DLB
such as a decrease in frontal cortex H1R in AD [42], and reduced
H2R expression in the hippocampus in both AD and DLB cases [35].
The functional consequence of increased H3R density could be a
further decrease in cognitive neurotransmitters and hence further
exacerbation of cognitive deﬁcits, and so would not be a positive
compensatory effect. Alternatively, the increase in H3R binding in
brains of individuals with more severe dementia could be simply
related to loss of cholinergic neurons. Loss of cholinergic neurons
in the basal forebrain is one of the most prominent and consistent
events occurring in AD [43]. These data support previous litera-
ture indicating that higher H3R binding correlated with more severe
dementia (MMSE) in AD [16], but this was more pronounced in the
pre-frontal cortex.
Now to consider other symptoms present in many of the cases
studied. There was  no correlation between H3R binding and sever-
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levation of [3H] GSK189254 binding sites in the globus pallidus was observed in DL
elationship was  oberved with the other brain structures investigated. (n = number
ty of depression in DLB and AD cases, suggesting that the H3R does
ot play a major role in depression symptoms associated with AD
nd DLB. This is consistent with recent studies in depressed and
ipolar patients [44,45]. This lack of correlation held for most brains
tudied herein in terms of the psychotic symptoms. However, an
nteresting exception was the globus pallidus, where H3R binding
evels positively correlated with presence of signiﬁcant psychotic
ymptoms, particularly levels of delusion and, to a lesser extent
isual hallucinations, in both DLB and AD cases. DLB cases with
oderate to high delusion and visual hallucination scores displayed
pproximately 40% and 22% higher globus pallidus H3R binding in DLB cases in (G) Nucleus Accumbens, (H)  combined Globus Pallidus. A signiﬁcant
s with severe delusion compared to cases lacking delusions (p < 0.05). No signiﬁcant
ividual patient cases).
densities, respectively, in comparison to cases lacking such psy-
chotic symptoms. A similar trend was  present in AD cases with
moderate to high delusion and visual hallucination scores displayed
approximately 37% and 14% higher H3R binding densities, respec-
tively in comparison to cases lacking such psychotic symptoms.
It has been previously reported that the globus pallidus is spared
of pathology in Lewy body diseases, DLB and PDD [46]. However,
the volume of the human globus pallidus has also been positively
correlated with the severity of global psychotic symptoms, as mea-
sured by both the Scale for the Assessment of Negative Symptoms
and Positive Symptoms [47], which may  account for this appar-
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levation of [3H] GSK189254 in the globus pallidus was observed in DLB cases with
tructures investigated (n = number of individual patient cases).
nt increase in the H3R. This ﬁnding was more profound in the
LB cases than AD cases and this is to be expected since DLB cases
ave generally more pronounced psychotic symptomology than AD
ases. H3R expression has been shown to be altered in patients
ith Schizophrenia and is thought to be involved in the under-
ying neuropathology [48]. The study showed signiﬁcantly higher
istamine H3R radioligand binding sites in the prefrontal cortex of
he schizophrenic group and bipolar subjects with psychotic symp-
oms, and higher H3R binding correlated with psychotic symptoms,
s seen in this present study [48]. H3Rs in the human prefrontal
ortex is thought to be involved in the modulation of cognition and
motional behaviours, and this is supported by ﬁndings in animals
hat H3R antagonists enhance prepulse inhibition and cognitive
erformance [49–51]. Early promise with pitolisant, a H3R antag- DLB cases in (G) Nucleus Accumbens, (H) combined Globus Pallidus. A signiﬁcant
l hallucinations (p < 0.05). No signiﬁcant relationship was see with the other brain
onist/inverse agonist for the psychotic symptoms in schizophrenic
patients [18,19], has not been conﬁrmed with another H3R antag-
onist, ABT-288 [17], with a distinct pharmacokinetic proﬁle. Such
studies are still lacking, however, in Lewy body dementia patients,
DLB and PDD. The main limitation common to this type of study lies
in the relatively small number of cases investigated. The quality of
the case tissue and respective clinical information from a leading
DLB brain bank centre is a strength of this study, but naturally,
further studies are required to conﬁrm these interesting ﬁndings
utilizing cases from other international brain banks. Furthermore,
future studies are also required to probe other key brain structures
implicated in psychotic symptoms in DLB and PDD cases.
In conclusion, the key novel ﬁndings were the general preserva-
tion or elevated levels of the H3R in both normal ageing humans and
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